Anna Rowe

University of Birmingham

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (9)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (9)

Mark Thomas

University of Birmingham

UNITED KINGDOM

View details

Rachel Cooney

Honorary Senior Lecturer

University of Birmingham

UNITED KINGDOM

View details

Gideon M. Hirschfield

CANADA

View details

Dhruv Parekh

University of Birmingham

UNITED KINGDOM

View details

James Scriven

Senior Clinical Lecturer

University of Birmingham

UNITED KINGDOM

View details

Victoria Homer

University of Birmingham

UNITED KINGDOM

View details

Joanna Porter

University College London

UNITED KINGDOM

View details

Tony Whitehouse

University of Birmingham

UNITED KINGDOM

View details

Yuk Ting Ma

University of Birmingham

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Anna Rowe

Research Interests

Explore related searches

Contact this professor

Articles (9)

Addition of Dendritic Cell Vaccination to Conditioning Cyclophosphamide and Chemoembolization in Patients with Hepatocellular Carcinoma: The ImmunoTACE Trial

Addition of a dendritic cell vaccine to conditioning cyclophosphamide and chemoembolisation to prolong progression-free survival in patients with hepatocellular carcinoma: the ImmunoTACE RCT

FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trial.

Vascular adhesion protein-1 blockade in primary sclerosing cholangitis: Open-label, multicenter, single-arm, phase II trial

Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial

Monoclonal antibody BTT1023 targeting vascular adhesion protein 1 for treating primary sclerosing cholangitis: BUTEO single-arm Phase II trial

A randomised phase II clinical trial of low-dose cyclophosphamide and transarterial chemoembolization (TACE) with or without vaccination with dendritic cells (DC) pulsed with HepG2 lysate ex vivo in patients with hepatocellular carcinoma (HCC): The ImmunoTACE trial.

The value of patient-reported outcomes in early-phase clinical trials.

CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults

Collaborators (9)

Mark Thomas

Rachel Cooney

Gideon M. Hirschfield

Dhruv Parekh

James Scriven

Victoria Homer

Joanna Porter

Tony Whitehouse

Yuk Ting Ma

Make your next move.